|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US7459540B1
(en)
*
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
DE60232265D1
(de)
*
|
2001-10-25 |
2009-06-18 |
Genentech Inc |
Glycoprotein-zusammensetzungen
|
|
ES2500918T3
(es)
|
2001-12-21 |
2014-10-01 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina e interferón beta
|
|
CA2484556A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US20070161087A1
(en)
*
|
2003-05-29 |
2007-07-12 |
Wolfgang Glaesner |
Glp-1 fusion proteins
|
|
SI1641823T1
(sl)
*
|
2003-06-12 |
2011-12-30 |
Lilly Co Eli |
Fuzijski proteini analogni glp-1
|
|
CN102816241B
(zh)
|
2004-02-09 |
2015-07-22 |
人类基因科学公司 |
清蛋白融合蛋白
|
|
EP1831252B1
(en)
*
|
2004-12-22 |
2009-07-01 |
Eli Lilly And Company |
Glp-1 analog fusion protein formulations
|
|
WO2006124529A1
(en)
*
|
2005-05-13 |
2006-11-23 |
Eli Lilly And Company |
Glp-1 pegylated compounds
|
|
WO2007012188A1
(en)
*
|
2005-07-27 |
2007-02-01 |
Qinghua Wang |
GLP/1/EXENDM 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
|
|
EP1924293A4
(en)
|
2005-08-06 |
2008-12-24 |
Qinghua Wang |
COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF DIABETES TYPE I
|
|
PT1767545E
(pt)
*
|
2005-09-22 |
2010-02-05 |
Biocompatibles Uk Ltd |
Polipéptidos de fusão glp-1 (péptido 1 do tipo glucagom) com resistência aumentada à peptidase
|
|
AU2006321743A1
(en)
*
|
2005-10-24 |
2007-06-14 |
Centocor, Inc. |
GLP-2 mimetibodies, polypeptides, compositions, methods and uses
|
|
PT1965823T
(pt)
|
2005-11-04 |
2016-08-18 |
Glaxosmithkline Llc |
Métodos para administração de agentes hipoglicémicos
|
|
WO2007056362A2
(en)
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
US8178495B2
(en)
|
2008-06-27 |
2012-05-15 |
Duke University |
Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
|
|
EP1816201A1
(en)
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
|
WO2007124461A2
(en)
|
2006-04-20 |
2007-11-01 |
Amgen Inc. |
Glp-1 compounds
|
|
EP2076604A4
(en)
*
|
2006-08-31 |
2009-09-02 |
Centocor Ortho Biotech Inc |
GLP-2 MIMIC BODIES, POLYPEPTIDES, COMPOSITIONS, PROCESSES AND USES
|
|
MX2009002547A
(es)
*
|
2006-09-06 |
2009-06-19 |
Phasebio Pharmaceuticals Inc |
Composiciones terapeuticas de peptido de fusion.
|
|
US8338376B2
(en)
*
|
2006-10-20 |
2012-12-25 |
Biogen Idec Ma Inc. |
Compositions comprising variant LT-B-R-IG fusion proteins
|
|
US8754194B2
(en)
|
2006-12-22 |
2014-06-17 |
Csl Behring Gmbh |
Modified coagulation factors with prolonged in vivo half-life
|
|
US8669228B2
(en)
*
|
2007-01-05 |
2014-03-11 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
|
|
AU2011254001B2
(en)
*
|
2007-01-05 |
2012-08-02 |
Covx Technologies Ireland Limited |
Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
|
|
JP2008169195A
(ja)
|
2007-01-05 |
2008-07-24 |
Hanmi Pharmaceutical Co Ltd |
キャリア物質を用いたインスリン分泌ペプチド薬物結合体
|
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
|
EP2526962B1
(en)
|
2007-02-12 |
2019-08-14 |
CSL Behring GmbH |
Therapeutic application of Kazal-type serine protease inhibitors
|
|
EP2487184A1
(en)
|
2007-02-15 |
2012-08-15 |
Indiana University Research and Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
|
EP2139509A2
(en)
*
|
2007-03-15 |
2010-01-06 |
Biogen Idec MA, Inc. |
Treatment of autoimmune disorders
|
|
RU2539829C2
(ru)
*
|
2007-06-19 |
2015-01-27 |
ГЛИТЕК,ИНК.,Япония |
Пептид glp-1 с присоединенной олигосахаридной цепью
|
|
EP3260129A1
(en)
|
2007-08-03 |
2017-12-27 |
Eli Lilly and Company |
An fgf-21 compound and a glp-1 compound for use in the treatment of obesity
|
|
US7960336B2
(en)
|
2007-08-03 |
2011-06-14 |
Pharmain Corporation |
Composition for long-acting peptide analogs
|
|
US8563527B2
(en)
*
|
2007-08-20 |
2013-10-22 |
Pharmain Corporation |
Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
|
|
EP2031064A1
(de)
*
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
|
ES2509883T3
(es)
|
2007-10-30 |
2014-10-20 |
Indiana University Research And Technology Corporation |
Antagonistas de glucagón
|
|
ES2558155T3
(es)
*
|
2007-10-30 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
|
|
US20100317057A1
(en)
*
|
2007-12-28 |
2010-12-16 |
Novo Nordisk A/S |
Semi-recombinant preparation of glp-1 analogues
|
|
AU2009210570B2
(en)
*
|
2008-01-30 |
2014-11-20 |
Indiana University Research And Technology Corporation |
Ester-based insulin prodrugs
|
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
|
CL2009001424A1
(es)
|
2008-06-17 |
2010-04-30 |
Univ Indiana Res & Tech Corp |
Peptido tipo glucagon; dimero que comprende dos de dichos peptidos; composicion farmaceutica que lo comprende; y su uso para tratar diabetes o inducir perdida de peso.
|
|
US9062124B2
(en)
*
|
2008-06-17 |
2015-06-23 |
Indiana University Research And Technology Corporation |
GIP-based mixed agonists for treatment of metabolic disorders and obesity
|
|
AU2009260301B2
(en)
*
|
2008-06-17 |
2015-09-03 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
|
|
DK2291523T3
(en)
|
2008-06-24 |
2015-03-23 |
Csl Behring Gmbh |
Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
|
|
CA2739615C
(en)
|
2008-10-10 |
2017-12-05 |
Amgen Inc. |
Fgf21 mutants comprising polyethylene glycol and uses thereof
|
|
EP2376097A4
(en)
|
2008-12-19 |
2012-10-03 |
Univ Indiana Res & Tech Corp |
AMID-BASED PEPTIDE PRODRUGS OF THE GLUCAGON SUPERFAMILY
|
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
|
AU2010246108B2
(en)
|
2009-05-05 |
2014-10-23 |
Amgen Inc. |
FGF21 mutants and uses thereof
|
|
CA2760674A1
(en)
|
2009-05-05 |
2010-11-11 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
|
CA2765026A1
(en)
|
2009-06-16 |
2010-12-23 |
Indiana University Research And Technology Corporation |
Gip receptor-active glucagon compounds
|
|
JP2012530493A
(ja)
*
|
2009-06-17 |
2012-12-06 |
アムジエン・インコーポレーテツド |
キメラポリペプチドおよびその使用
|
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
|
WO2011043530A1
(ko)
*
|
2009-10-09 |
2011-04-14 |
(주)알테오젠 |
Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
|
|
WO2011068893A1
(en)
*
|
2009-12-02 |
2011-06-09 |
Amgen Inc. |
BINDING PROTEINS THAT BIND TO HUMAN FGFR1C, HUMAN β-KLOTHO AND BOTH HUMAN FGFR1C AND HUMANβ-KLOTHO
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
US8703701B2
(en)
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
|
BR112012018585A2
(pt)
|
2010-01-27 |
2017-01-10 |
Univ Indiana Res & Tech Corp |
conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade
|
|
EP2371857A1
(en)
|
2010-04-01 |
2011-10-05 |
CSL Behring GmbH |
Factor XII inhibitors for treating interstitial lung disease
|
|
CA2796055A1
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
Human fgf receptor and .beta.-klotho binding proteins
|
|
MX2012012383A
(es)
|
2010-04-30 |
2012-11-30 |
Sanwa Kagaku Kenkyusho Co |
Peptido para mejorar la bioestabilidad de una sustancia bioactica y sustancia bioactiva que tiene bioestabilidad mejorada.
|
|
BR112012028707A2
(pt)
|
2010-05-13 |
2019-09-24 |
Univ Indiana Res & Tech Corp |
composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo.
|
|
US9127088B2
(en)
|
2010-05-13 |
2015-09-08 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
|
|
CN101891823B
(zh)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
|
MX2012014576A
(es)
|
2010-06-24 |
2013-02-21 |
Univ Indiana Res & Tech Corp |
Profarmacos de peptido de la superfamilia de glucagon basado en amida.
|
|
WO2012010553A1
(en)
|
2010-07-20 |
2012-01-26 |
Novo Nordisk A/S |
N-terminal modified fgf21 compounds
|
|
EA201390941A1
(ru)
|
2010-12-22 |
2013-12-30 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Аналоги глюкагона, проявляющие активность на рецепторе gip
|
|
CA2824143C
(en)
|
2011-01-14 |
2018-12-18 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
|
EP2497489A1
(en)
|
2011-03-09 |
2012-09-12 |
CSL Behring GmbH |
Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
|
|
ES2646191T3
(es)
|
2011-03-09 |
2017-12-12 |
Csl Behring Gmbh |
Inhibidores de Factor XII para la administración con procedimientos médicos que comprenden contacto con superficies artificiales
|
|
JP5926791B2
(ja)
|
2011-03-29 |
2016-05-25 |
ロシュ グリクアート アーゲー |
抗体Ｆｃ変種
|
|
RS56173B1
(sr)
|
2011-06-22 |
2017-11-30 |
Univ Indiana Res & Tech Corp |
Koagonisti receptora za glukagon/glp-1 receptora
|
|
CA2839867A1
(en)
|
2011-06-22 |
2012-12-27 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
|
BR112014001104B1
(pt)
|
2011-07-22 |
2022-12-06 |
Csl Behring Gmbh |
Anticorpo monoclonal antifator xii/xiia-beta ou fragmento de ligação ao antígeno do mesmo, seu método de produção, ácido nucleico, vetor, dispositivo médico e composição farmacêutica
|
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
|
KR20130049671A
(ko)
|
2011-11-04 |
2013-05-14 |
한미사이언스 주식회사 |
생리활성 폴리펩타이드 결합체 제조 방법
|
|
JP6324315B2
(ja)
|
2011-11-17 |
2018-05-16 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
|
|
EP2623110A1
(en)
|
2012-01-31 |
2013-08-07 |
CSL Behring GmbH |
Factor XII inhibitors for the treatment of neurological inflammatory disorders
|
|
EP2814502B1
(en)
|
2012-02-15 |
2017-09-13 |
CSL Behring GmbH |
Von willebrand factor variants having improved factor viii binding affinity
|
|
RU2015101697A
(ru)
|
2012-06-21 |
2016-08-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Аналоги глюкагона, обладающие активностью рецептора gip
|
|
AU2013288641B2
(en)
|
2012-07-13 |
2017-07-06 |
Roche Glycart Ag |
Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
|
WO2014043361A1
(en)
*
|
2012-09-12 |
2014-03-20 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
|
US9474803B2
(en)
|
2012-11-27 |
2016-10-25 |
Alteogen Inc. |
Composition for stabilizing fusion protein in which protein and FC domain are fused
|
|
KR102521039B1
(ko)
|
2012-11-27 |
2023-04-12 |
바이오마린 파머수티컬 인크. |
표적화된 치료적 리소좀 효소 융합 단백질들 및 그들의 용도들
|
|
WO2014135694A1
(en)
|
2013-03-08 |
2014-09-12 |
Csl Behring Ag |
Treatment and prevention of remote ischemia-reperfusion injury
|
|
CA2902530C
(en)
|
2013-03-11 |
2023-05-09 |
Genzyme Corporation |
Site-specific antibody-drug conjugation through glycoengineering
|
|
CA2904332A1
(en)
|
2013-03-14 |
2014-10-02 |
Indiana University Research And Technology Corporation |
Insulin-incretin conjugates
|
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
EP2796145B1
(en)
|
2013-04-22 |
2017-11-01 |
CSL Ltd. |
A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
|
|
WO2014207199A1
(en)
|
2013-06-28 |
2014-12-31 |
Csl Behring Gmbh |
Combination therapy using a factor xii inhibitor and a c1-inhibitor
|
|
CN103408669B
(zh)
*
|
2013-08-01 |
2016-01-20 |
江苏泰康生物医药有限公司 |
Glp-1类似物融合蛋白，及其制备方法和用途
|
|
CN104592381A
(zh)
*
|
2013-10-31 |
2015-05-06 |
江苏万邦生化医药股份有限公司 |
一种利拉鲁肽中间体多肽的制备方法
|
|
WO2015138278A1
(en)
|
2014-03-11 |
2015-09-17 |
Novartis Ag |
Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
|
|
PT3129067T
(pt)
|
2014-03-19 |
2023-03-22 |
Genzyme Corp |
Glicomanipulação em sítios específicos de frações de direcionamento
|
|
CN117065044A
(zh)
*
|
2014-03-31 |
2023-11-17 |
韩美药品株式会社 |
通过使用免疫球蛋白Fc片段连接改善蛋白质和肽的溶解度的方法
|
|
ES2886859T3
(es)
|
2014-06-18 |
2021-12-21 |
Csl Behring Gmbh |
Terapia usando un inhibidor del factor xii en un trastorno neurotraumático
|
|
CA2953593C
(en)
|
2014-07-02 |
2023-09-26 |
Csl Limited |
Modified von willebrand factor
|
|
HUE046065T2
(hu)
|
2014-07-21 |
2020-01-28 |
Delinia Inc |
Szabályozó T-sejteket szelektíven aktiváló molekulák autoimmun betegségek kezelésére
|
|
CN113234138A
(zh)
|
2014-08-11 |
2021-08-10 |
德里尼亚公司 |
选择性地活化调节性t细胞用于治疗自身免疫病的修饰的il-2变体
|
|
EP3206710B1
(en)
|
2014-09-24 |
2020-05-06 |
Indiana University Research & Technology Corporation |
Incretin-insulin conjugates
|
|
CN104293834B
(zh)
*
|
2014-10-11 |
2018-03-23 |
上海兴迪金生物技术有限公司 |
GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法
|
|
EP3236991B1
(en)
|
2014-12-23 |
2019-06-19 |
Novo Nordisk A/S |
Fgf21 derivatives and uses thereof
|
|
KR101825048B1
(ko)
*
|
2014-12-31 |
2018-02-05 |
주식회사 제넥신 |
GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
|
|
UA126270C2
(uk)
|
2015-04-10 |
2022-09-14 |
Емджен Інк. |
Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин
|
|
AR105616A1
(es)
*
|
2015-05-07 |
2017-10-25 |
Lilly Co Eli |
Proteínas de fusión
|
|
ES2774011T3
(es)
|
2015-05-22 |
2020-07-16 |
CSL Behring Lengnau AG |
Polipéptidos del factor de von Willebrand truncado para tratar la hemofilia
|
|
KR20180012303A
(ko)
|
2015-05-22 |
2018-02-05 |
체에스엘 베링 리컴비넌트 퍼실리티 아게 |
변형된 폰 빌레브란트 인자의 제조 방법
|
|
TWI622596B
(zh)
|
2015-10-26 |
2018-05-01 |
美國禮來大藥廠 |
升糖素受體促效劑
|
|
KR102670157B1
(ko)
|
2015-10-28 |
2024-05-29 |
주식회사유한양행 |
이중 작용 단백질 및 이를 포함하는 약학적 조성물
|
|
KR102668200B1
(ko)
|
2015-10-28 |
2024-05-23 |
주식회사유한양행 |
지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
|
|
EP3184149A1
(en)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Soluble glycoprotein v for treating thrombotic diseases
|
|
CN109715662B
(zh)
|
2015-12-23 |
2023-07-21 |
美国安进公司 |
使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
|
|
SG11201805494WA
(en)
|
2016-01-07 |
2018-07-30 |
Csl Behring Recombinant Facility Ag |
Mutated von willebrand factor
|
|
JP6851381B6
(ja)
|
2016-01-07 |
2021-04-21 |
ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト |
変異切断型フォンウィルブランド因子
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
WO2017173494A1
(en)
|
2016-04-06 |
2017-10-12 |
Csl Limited |
Method of treating atherosclerosis
|
|
CA3019398A1
(en)
|
2016-04-26 |
2017-11-02 |
R.P. Scherer Technologies, Llc |
Antibody conjugates and methods of making and using the same
|
|
US10336812B2
(en)
|
2016-05-10 |
2019-07-02 |
Janssen Biotech, Inc. |
GDF15 fusion proteins and uses thereof
|
|
CN107759696A
(zh)
|
2016-08-19 |
2018-03-06 |
安源医药科技（上海）有限公司 |
人白介素7融合蛋白及其制备方法
|
|
WO2018032638A1
(zh)
|
2016-08-19 |
2018-02-22 |
安源医药科技（上海）有限公司 |
用于构建融合蛋白的连接肽
|
|
CN106279437B
(zh)
|
2016-08-19 |
2017-10-31 |
安源医药科技（上海）有限公司 |
高糖基化人凝血因子viii融合蛋白及其制备方法与用途
|
|
SG11201903882VA
(en)
|
2016-11-08 |
2019-05-30 |
Delinia Inc |
Il-2 variants for the treatment of autoimmune diseases
|
|
CN110121355B
(zh)
|
2016-11-10 |
2023-09-12 |
株式会社柳韩洋行 |
用于预防或治疗肝炎、肝纤维化和肝硬化的包含融合蛋白的药物组合物
|
|
DK3538134T3
(da)
|
2016-11-11 |
2022-02-07 |
CSL Behring Lengnau AG |
Trunkeret von willebrand-faktor polypeptider til ekstravaskulær administration til behandling eller profylakse af en blodkoagulationsforstyrrelse
|
|
AU2017358861B2
(en)
|
2016-11-11 |
2022-02-17 |
CSL Behring Lengnau AG |
Truncated von Willebrand Factor polypeptides for treating hemophilia
|
|
EP3351262A1
(en)
|
2016-12-30 |
2018-07-25 |
Istanbul Universitesi Rektorlugu |
Curaglutide for in treatment of prediabetes, diabetes, obesity and metabolic diseases associated thereto
|
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
|
US11560416B2
(en)
|
2017-04-21 |
2023-01-24 |
Yuhan Corporation |
Method for producing dual function proteins and its derivatives
|
|
EP3630164B1
(en)
|
2017-06-01 |
2023-08-23 |
Eli Lilly and Company |
Dulaglutide for the treatment of chronic kidney disease
|
|
AU2018287215A1
(en)
|
2017-06-22 |
2020-02-06 |
CSL Behring Lengnau AG |
Modulation of FVIII immunogenicity by truncated VWF
|
|
KR20200054303A
(ko)
|
2017-09-22 |
2020-05-19 |
리제너론 파아마슈티컬스, 인크. |
글루카곤 유사 펩타이드 1 수용체 작용제 및 이의 용도
|
|
CN111356472A
(zh)
|
2017-11-21 |
2020-06-30 |
伊莱利利公司 |
使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物
|
|
WO2019119673A1
(zh)
|
2017-12-19 |
2019-06-27 |
北京吉源生物科技有限公司 |
一种双基因修饰的干细胞及其用途
|
|
WO2019125003A1
(ko)
*
|
2017-12-22 |
2019-06-27 |
케이비바이오메드 주식회사 |
경구용 유전자 전달체 및 이의 용도
|
|
WO2019140021A1
(en)
|
2018-01-12 |
2019-07-18 |
Eli Lilly And Company |
Combination therapy
|
|
CN110128525B
(zh)
|
2018-02-08 |
2022-08-26 |
广东东阳光药业有限公司 |
Fgf21变体、融合蛋白及其应用
|
|
KR20200135618A
(ko)
|
2019-05-23 |
2020-12-03 |
㈜ 디앤디파마텍 |
폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
|
|
JP2021530533A
(ja)
|
2018-07-19 |
2021-11-11 |
ディーアンドディー ファーマテック インコーポレイテッド |
ポリペプチドを含む医薬組成物
|
|
CN110878127B
(zh)
|
2018-09-06 |
2022-06-28 |
浙江柏拉阿图医药科技有限公司 |
长效重组GLP1-Fc-CD47蛋白及其制备和用途
|
|
CN111234000B
(zh)
*
|
2018-11-28 |
2023-05-26 |
鲁南制药集团股份有限公司 |
艾塞纳肽类似物
|
|
CN111269312B
(zh)
*
|
2018-12-04 |
2023-05-09 |
鲁南制药集团股份有限公司 |
一种异源融合蛋白质
|
|
CN109836486B
(zh)
*
|
2019-01-30 |
2020-09-08 |
北京双因生物科技有限公司 |
成纤维生长因子21变体、其融合蛋白及其用途
|
|
CA3123325A1
(en)
*
|
2019-03-05 |
2020-09-10 |
Sunshine Lake Pharma Co., Ltd. |
A polypeptide molecule and application thereof
|
|
EP3934679A1
(en)
|
2019-03-08 |
2022-01-12 |
Amgen Inc. |
Growth differentiation factor 15 combination therapy
|
|
US20220143187A1
(en)
|
2019-03-15 |
2022-05-12 |
Eli Lilly And Company |
Preserved formulations
|
|
CA3056663C
(en)
|
2019-04-05 |
2022-10-18 |
Jeffrey S. RIESMEYER |
Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
|
|
CN114007639A
(zh)
|
2019-05-17 |
2022-02-01 |
苏黎世大学 |
用于治疗出血性中风后不良继发性神经学后果的触珠蛋白
|
|
AU2020300820A1
(en)
|
2019-07-04 |
2022-03-03 |
CSL Behring Lengnau AG |
A truncated von willebrand factor (vWF) for increasing the in vitro stability of coagulation factor VIII
|
|
JP2022552323A
(ja)
|
2019-10-15 |
2022-12-15 |
イーライ リリー アンド カンパニー |
組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
|
|
US20220348637A1
(en)
|
2019-11-11 |
2022-11-03 |
CSL Behring Lengnau AG |
Polypeptides for inducing tolerance to factor viii
|
|
WO2021139744A1
(en)
|
2020-01-11 |
2021-07-15 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Conjugates of fusion proteins of glp-1 and fgf21
|
|
US11981718B2
(en)
|
2020-05-27 |
2024-05-14 |
Ampsource Biopharma Shanghai Inc. |
Dual-function protein for lipid and blood glucose regulation
|
|
MX2023002293A
(es)
|
2020-08-24 |
2023-05-19 |
Univ Pennsylvania |
Vectores virales que codifican fusiones de agonistas del receptor de glp-1 y usos de estos en el tratamiento de enfermedades metabólica.
|
|
CN114106194B
(zh)
*
|
2020-08-31 |
2024-01-16 |
中国科学院天津工业生物技术研究所 |
一种用于治疗糖尿病和/或肥胖症的融合蛋白
|
|
CA3198740A1
(en)
|
2020-11-20 |
2022-05-27 |
John Roberts |
Method for treating antibody-mediated rejection
|
|
CN114685644A
(zh)
|
2020-12-29 |
2022-07-01 |
苏州康宁杰瑞生物科技有限公司 |
一种人glp-1多肽变体及其应用
|
|
WO2022162218A1
(en)
|
2021-02-01 |
2022-08-04 |
Csl Behring Ag |
Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
|
|
JP2024517857A
(ja)
|
2021-05-07 |
2024-04-23 |
ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト |
組換えハプトグロビン（Ｈｐ）ベータ鎖を作製するための発現系
|
|
KR20240029769A
(ko)
|
2021-07-06 |
2024-03-06 |
수조우 알파맵 씨오., 엘티디. |
융합단백질 및 이의 응용
|
|
TW202409070A
(zh)
|
2022-05-18 |
2024-03-01 |
美商普羅托莫科技公司 |
芳族含硼化合物及相關胰島素類似物
|
|
CN114774496B
(zh)
*
|
2022-06-21 |
2022-10-04 |
北京惠之衡生物科技有限公司 |
一种高密度发酵制备glp-1类似物的方法
|
|
WO2024047219A1
(en)
|
2022-09-02 |
2024-03-07 |
Csl Behring Ag |
Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction
|
|
WO2024064842A1
(en)
|
2022-09-21 |
2024-03-28 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating obesity, diabetes, and liver dysfunction
|
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|